Ionis Pharmaceuticals
IONS
Performance
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biopharmaceutical company focused on discovering and delivering RNA- and DNA-targeted medicines to address serious diseases. Through antisense chemistry and innovative genetic therapies, the company pursues treatments across neurology, cardiometabolic disorders, and select rare diseases, aiming to improve patient outcomes globally. Headquartered in Carlsbad, California, Ionis combines scientific expertise with a deep pipeline to advance next-generation therapies from research to clinical development.
Recent News
Drug Trials Snapshot: TRYNGOLZA
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.
Deep Dive: Huntington’s at a Crossroads
Goldman Sachs Sets New Biogen Stock Price Target on Bold Alzheimer's Bet
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
BridgeBio’s Attruby Challenges Pfizer’s Vyndamax Legacy in Pivotal ATTR Trial
Hepatitis B: Are We Edging Closer to a Cure?
EU Approves Otsuka's Long-Acting HAE Drug Dawnzera
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
FDA Grants Priority Review and Breakthrough Designation to GSK‑Ionis Hepatitis B Drug Bepirovirsen
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
2025 Novel Large Molecule FDA Drug Approvals
Intellia Files FDA BLA After Phase 3 Shows 87% Cut in HAE Attacks
Tweedy, Browne Co LLC Top Holdings, Trades & Investment Strategy
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Transcript
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
Patent Losses Hit Novartis Hard, but CEO Has a Plan
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
GSK‑Ionis Antisense Drug Bepirovirsen Gets FDA Priority Review, Breakthrough Designation
Recent Deals
No recent deals for this company.